AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine plus Valproic acid
Number of subjects: 6
Study 9024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 6
Study 9024246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bromocriptine, cyproheptadine, and valproic acid
Number of subjects: 6
Study 8031230 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive program (vouchers for retail items contingent on submitting cocaine-free urine specimens)
Number of subjects: 40
Study 8031230 — intervention group
Group type: COMPARATOR
Intervention: No incentives (no vouchers)
Number of subjects: 40
Study 3056447 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 99
Study 3056447 — intervention group
Group type: EXPERIMENTAL
Intervention: Capozide (captopril, 25 mg with 15 mg hydrochlorothiazide)
Number of subjects: 99
Study 3056447 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice daily)
Number of subjects: 99
Study 3056447 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 31190588 — intervention group
Group type: EXPERIMENTAL
Intervention: High mental effort during reading and speaking tasks
Number of subjects: 104
Study 31190588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mental effort during reading and speaking tasks
Number of subjects: 104
Study 31190588 — intervention group
Group type: EXPERIMENTAL
Intervention: High mental effort followed by a period of relaxation
Number of subjects: 104
Study 31244318 — intervention group
Group type: EXPERIMENTAL
Intervention: Health beliefs related to perceived severity, benefits, motivator factors, and cues to action.
Number of subjects: 520
Study 31244318 — intervention group
Group type: EXPERIMENTAL
Intervention: Health beliefs related to perceived severity, susceptibility, motivator factors, and self-efficacy.
Number of subjects: 520
Study 31244318 — intervention group
Group type: EXPERIMENTAL
Intervention: Action stage of mammography adoption.
Number of subjects: 520
Study 31244318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-contemplation, relapse, and contemplation stages of mammography adoption.
Number of subjects: 520
Study 27566475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injections
Number of subjects: 41
Study 27566475 — intervention group
Group type: COMPARATOR
Intervention: Blind injections
Number of subjects: 41
Study 25412712 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention Group (BIG)
Number of subjects: 476
Study 25412712 — intervention group
Group type: COMPARATOR
Intervention: Contact-Control Group (CCG)
Number of subjects: 476
Study 25412712 — intervention group
Group type: COMPARATOR
Intervention: No-Contact-Control Group (NCG)
Number of subjects: 476
Study 23681293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop signal in selective response inhibition tasks
Number of subjects: 0
Study 23681293 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved control of stop signal influences
Number of subjects: 0
Study 23681293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized readiness potential measurement
Number of subjects: 0
Study 22655499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless aortic valve (SAV)
Number of subjects: 225
Study 22655499 — intervention group
Group type: COMPARATOR
Intervention: Conventional stented bioprosthesis (CSB)
Number of subjects: 225
Study 19862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (vinorelbine and gemcitabine followed by docetaxel, or paclitaxel and carboplatin)
Number of subjects: 387
Study 16856621 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (peg‐INF)‐alpha2a 180 microg/week plus ribavirin 800 mg/d for 12 weeks, followed by extended treatment for 72 weeks (extension arm)
Number of subjects: 110
Study 16856621 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (12 weeks)
Number of subjects: 110
Study 16856621 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (peg‐INF)‐alpha2a 180 microg/week plus ribavirin 800 mg/d for 12 weeks, followed by additional 12 or 36 weeks depending on genotype for those achieving EVR
Number of subjects: 110
Study 12538787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition and 20 mL breast milk/kg/d (BM)
Number of subjects: 38
Study 12538787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition and 20 mL formula/kg/d (F)
Number of subjects: 38
Study 12538787 — intervention group
Group type: COMPARATOR
Intervention: Solely parenteral nutrition (C)
Number of subjects: 38
Study 11057498 — intervention group
Group type: EXPERIMENTAL
Intervention: New hub device
Number of subjects: 130
Study 11057498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard good clinical procedures)
Number of subjects: 130
Study 9055140 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of H1 blocker dimetindene maleate (0.1 mg/kg) and H2 blocker cimetidine (5 mg/kg)
Number of subjects: 30
Study 9055140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8416660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (2.1 MJ-deficit/d for 16 weeks) with formal exercise instruction
Number of subjects: 19
Study 8416660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (2.1 MJ-deficit/d for 16 weeks) with informal exercise instruction
Number of subjects: 19
Study 3314726 — intervention group
Group type: EXPERIMENTAL
Intervention: Human pituitary growth hormone
Number of subjects: 20
Study 3314726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29076581 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 120
Study 29076581 — intervention group
Group type: EXPERIMENTAL
Intervention: Blowing into a spirometer
Number of subjects: 120
Study 29076581 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing a stress ball
Number of subjects: 120
Study 29076581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 28345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Iodixanol 320 and 80 Kvp tube voltage)
Number of subjects: 200
Study 28345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Iodixanol 320 and 100 Kvp tube voltage)
Number of subjects: 200
Study 28345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (Iomeprol 400 and 80 Kvp tube voltage)
Number of subjects: 200
Study 28345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (Iomeprol 400 and 100 Kvp tube voltage)
Number of subjects: 200
Study 28345174 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with 80 kV
Number of subjects: 200
Study 26082504 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz with daily rifapentine and isoniazid
Number of subjects: 87
Study 24229539 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 137
Study 24229539 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational parenting intervention (PPI)
Number of subjects: 137
Study 24229539 — intervention group
Group type: COMPARATOR
Intervention: Community standard (CS)
Number of subjects: 137
Study 24229539 — intervention group
Group type: COMPARATOR
Intervention: Nonmaltreated comparison (NC)
Number of subjects: 137
Study 20085176 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh-containing preparations
Number of subjects: 9
Study 20085176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18295937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (633 ml)
Number of subjects: 5
Study 18295937 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (264 ml)
Number of subjects: 5
Study 18295937 — intervention group
Group type: COMPARATOR
Intervention: White wine (264 ml)
Number of subjects: 5
Study 18295937 — intervention group
Group type: COMPARATOR
Intervention: Whisky (79 ml)
Number of subjects: 5
Study 18295937 — intervention group
Group type: COMPARATOR
Intervention: Water (250 ml)
Number of subjects: 5
Study 16923409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous mononuclear bone marrow cells
Number of subjects: 200
Study 16923409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of peripheral mononuclear blood cells
Number of subjects: 200
Study 16923409 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study 14638501 — intervention group
Group type: COMPARATOR
Intervention: Intranasal ruprintrivir (8 mg) prophylaxis 5x/day for 5 days
Number of subjects: 202
Study 14638501 — intervention group
Group type: COMPARATOR
Intervention: Intranasal ruprintrivir (8 mg) prophylaxis 2x/day for 5 days
Number of subjects: 202
Study 14638501 — intervention group
Group type: COMPARATOR
Intervention: Intranasal ruprintrivir (8 mg) treatment 5x/day for 4 days
Number of subjects: 202
Study 14638501 — intervention group
Group type: COMPARATOR
Intervention: Intranasal ruprintrivir treatment
Number of subjects: 202
Study 10814771 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day
Number of subjects: 31
Study 10814771 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 25 mg/day
Number of subjects: 31
Study 10814771 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (both doses)
Number of subjects: 31
Study 8891147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLA; 500 mg given twice daily for nine doses)
Number of subjects: 41
Study 8891147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLA)
Number of subjects: 41
Study 8891147 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (AZ; 500 mg for the first dose and then 250 mg once daily for four doses)
Number of subjects: 41
Study 8891147 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (AZ)
Number of subjects: 41
Study 1642616 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose intravenous immunoglobulin
Number of subjects: 33
Study 1642616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 6678826 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15mg
Number of subjects: 8
Study 6678826 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15mg + Alcohol 0.5g/kg
Number of subjects: 8
Study 6678826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6678826 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 0.5g/kg
Number of subjects: 8
Study 31888234 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaranth oil (20 mL)
Number of subjects: 0
Study 31888234 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed oil (20 mL)
Number of subjects: 0
Study 29871673 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and Treat (TnT) intervention in intervention colleges (n=3)
Number of subjects: 480
Study 29871673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TnT) in control colleges (n=3)
Number of subjects: 480
Study 26362233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 62
Study 26362233 — intervention group
Group type: COMPARATOR
Intervention: Functional technique
Number of subjects: 62
Study 23506245 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin (target blood glucose 80‐130 mg/dL, 4·44‐7·21 mmol/L) for up to 72 h
Number of subjects: 1400
Study 23506245 — intervention group
Group type: COMPARATOR
Intervention: Standard sliding scale subcutaneous insulin (blood glucose range 80‐179 mg/dL, 4·44‐9·93 mmol/L) for up to 72 h
Number of subjects: 1400
Study 23506245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1400
Study 22453725 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 17
Study 22453725 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport above 5000 ft
Number of subjects: 17
Study 22453725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation above 5000 ft
Number of subjects: 17
Study 20808101 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and organizational aid
Number of subjects: 0
Study 20808101 — intervention group
Group type: COMPARATOR
Intervention: Standard consent
Number of subjects: 0
Study 18059592 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief PA counselling (2-4 min) from a health care provider
Number of subjects: 120
Study 18059592 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief PA counselling + intensive PA counselling from a PA counsellor (3 months)
Number of subjects: 120
Study 15746735 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker therapy with oral diltiazem 120 mg/daily
Number of subjects: 100
Study 15746735 — intervention group
Group type: COMPARATOR
Intervention: No calcium channel blocker therapy
Number of subjects: 100
Study 11985633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole monotherapy
Number of subjects: 0
Study 11985633 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study 11985633 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study 11985633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10594415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 90
Study 10594415 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of bupivacaine 0.5%/lignocaine 2% with 1:200,000 adrenaline
Number of subjects: 90
Study 10594415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with 1:200,000 adrenaline
Number of subjects: 90
Study 8675719 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard EMD protocol with eye movements
Number of subjects: 40
Study 8675719 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving audio stimulus in place of the eye movements
Number of subjects: 40
Study 8675719 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol with eyes resting on the hands
Number of subjects: 40
Study 8675719 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 40
Study 1369705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 60-90 mg/day (n = 9)
Number of subjects: 20
Study 1369705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study 7350052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 7350052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 0
Study 7350052 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls, asymptomatic diabetic patients, asymptomatic postsurgical patients)
Number of subjects: 0
Study 31928097 — intervention group
Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 115177
Study 31928097 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented TKA
Number of subjects: 115177
Study 31928097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid TKA
Number of subjects: 115177
Study 31928097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Hybrid TKA
Number of subjects: 115177
Study 31131904 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 30
Study 31131904 — intervention group
Group type: COMPARATOR
Intervention: M-Wire Reciproc
Number of subjects: 30
Study 28658109 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA
Number of subjects: 79
Study 28658109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra PLA
Number of subjects: 79
Study 28658109 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐Q
Number of subjects: 79
Study 28658109 — intervention group
Group type: EXPERIMENTAL
Intervention: SALT
Number of subjects: 79
Study 26743243 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell (APBSC) transplantation
Number of subjects: 68
Study 26743243 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 68
Study 23294168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% carmellose sodium with added lipid (Drop C‐L)
Number of subjects: 37
Study 23294168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% glycerine with added lipid (Drop G‐L)
Number of subjects: 37
Study 23294168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% carmellose sodium (Drop C)
Number of subjects: 37
Study 23294168 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 37
Study 19428142 — intervention group
Group type: EXPERIMENTAL
Intervention: Modality-specific attention training program
Number of subjects: 66
Study 19428142 — intervention group
Group type: COMPARATOR
Intervention: Educational lecture control program
Number of subjects: 66
Study 19815592 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program plus standard care
Number of subjects: 130
Study 19815592 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 130
Study 17046973 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity heuristic (index test)
Number of subjects: 1378
Study 17046973 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1378
Study 15657588 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy at diagnosis
Number of subjects: 50
Study 15657588 — intervention group
Group type: COMPARATOR
Intervention: Delayed parathyroidectomy (1 year later)
Number of subjects: 50
Study 11710858 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral autologous platelet-rich plasma wound treatment (APG) during standard deep-plane rhytidectomy
Number of subjects: 8
Study 11710858 — intervention group
Group type: COMPARATOR
Intervention: Non-APG-treated side
Number of subjects: 8
Study 9475316 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal respiratory distress syndrome group
Number of subjects: 9
Study 9475316 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 9
Study 9475316 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 9
Study 2884858 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 24
Study 2884858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28821365 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1mg/kg and ketamine 0.15mg/kg (MK group)
Number of subjects: 106
Study 28821365 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1mg/kg and placebo (MP group)
Number of subjects: 106
Study 27256093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab)
Number of subjects: 304
Study 27256093 — intervention group
Group type: COMPARATOR
Intervention: Combination CapeOX/mFOLFOX6-Bmab
Number of subjects: 304
Study 25540041 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (four weekly 30-minute calls and written resources)
Number of subjects: 394
Study 22810395 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row fixation
Number of subjects: 90
Study 22810395 — intervention group
Group type: COMPARATOR
Intervention: Double-row fixation
Number of subjects: 90
Study 20585226 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis using linear and generalized linear mixed models
Number of subjects: 0
Study 18776782 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous release of the A1 pulley using a #15 blade
Number of subjects: 36
Study 18776782 — intervention group
Group type: COMPARATOR
Intervention: Open release of the A1 pulley
Number of subjects: 36
Study 16837721 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether‐lumefantrine (Coartem)
Number of subjects: 137
Study 16837721 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (ASAQ)
Number of subjects: 137
Study 14554218 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept (25 mg s.q., twice/week)
Number of subjects: 20
Study 14554218 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 10927727 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 82
Study 10927727 — intervention group
Group type: COMPARATOR
Intervention: Needle-insertion control
Number of subjects: 82
Study 10927727 — intervention group
Group type: COMPARATOR
Intervention: No-needle relaxation control
Number of subjects: 82
Study 8881340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-preference stimuli
Number of subjects: 4
Study 8881340 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-preference stimuli
Number of subjects: 4
Study 8881340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-preference stimuli
Number of subjects: 4
Study 1555624 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine 600 mg i.v. single bolus
Number of subjects: 33
Study 1555624 — intervention group
Group type: COMPARATOR
Intervention: L-carnitine 500 mg i.v. equimolar dose
Number of subjects: 33
Study 1555624 — intervention group
Group type: COMPARATOR
Intervention: L-propionylcarnitine and L-carnitine
Number of subjects: 33
Study 2934779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.2 mg)
Number of subjects: 14
Study 2934779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30371302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 96
Study 30371302 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 96
Study 27908164 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE (sinogram affirmed iterative reconstruction)
Number of subjects: 23
Study 27908164 — intervention group
Group type: COMPARATOR
Intervention: FBP (filtered‐backprojection)
Number of subjects: 23
Study 24652109 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsedated techniques (VCE and uTNE)
Number of subjects: 136
Study 24652109 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on Barrett's esophagus (BE)
Number of subjects: 136
Study 24652109 — intervention group
Group type: EXPERIMENTAL
Intervention: History of undergoing screening tests and GI symptoms
Number of subjects: 136
Study 22403352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 33